Results 271 to 280 of about 265,851 (371)

Small Intestine in Psoriasis [PDF]

open access: bronze, 1967
Sam Shuster   +2 more
openalex   +1 more source

Pseudoainhum in psoriasis

open access: yesIndian Journal of Dermatology, 2012
Pradeep Kumar, Vijay Gandhi
openaire   +4 more sources

Exploring the Cutaneous Associations of Crohn's Disease: A Retrospective Study of 108 Patients

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background The integumentary system provides a window into the overall health of individuals and may display cutaneous manifestations of systemic disease. Crohn's Disease (CD) is a relapsing inflammatory bowel disease that exhibits a significant symptomatic burden on a global scale.
Max E. Oscherwitz   +4 more
wiley   +1 more source

Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities

open access: yesJAAD Case Reports, 2017
Caleb Jeon, BS   +6 more
doaj  

Successful Treatment of Erythroderma in a Psoriasis Patient, Developed After Anti‐IL‐17, Anti‐IL‐23 and Anti‐IL‐4/IL‐13 Treatment, With Deucravacitinib

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT We present the case of a 79‐year‐old female patient diagnosed with psoriasis who developed paradoxical drug reactions after administration of anti‐IL17 and anti‐IL‐23 inhibitors. Having shifted towards a rather eczematous phenotype, the patient received an anti‐IL‐4/IL‐3 inhibitor, subsequently developing erythroderma.
Tugce Guel   +4 more
wiley   +1 more source

Severe psoriasis vulgaris complicating pemphigus vulgaris: A case report. [PDF]

open access: yesMedicine (Baltimore)
Wang L, Guo G, Tang S, Sun S, Wu R.
europepmc   +1 more source

A 66‐Year‐old Woman With Submammary Brownish Hyperkeratotic Plaques

open access: yes
JEADV Clinical Practice, EarlyView.
Antonia Kössinger   +2 more
wiley   +1 more source

Treatment of Pyoderma Gangrenosum With Bimekizumab

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Pyoderma gangrenosum (PG) is an inflammatory neutrophilic dermatosis with no FDA‐approved treatments. Current therapies, including corticosteroids and immunomodulators, often show limited efficacy and nonspecific, conferring to higher risk of adverse events.
Kareena S. Garg   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy